Form 4: Viking Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Dorothy Elizabeth Kelly-Gemmell, a Director of Viking Therapeutics, Inc., reported multiple transactions in common stock on August 1, 2026.
Summary
- Grant/award: acquired 6,333 Common Stock, par value $0.00001 per share on August 1, 2026; holds 6,333 after (Direct).
- Grant/award: acquired 40,800 Stock Option (Right to Buy) on August 1, 2026; holds 40,800 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dorothy Elizabeth Kelly-Gemmell — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-01 | Grant/award | Common Stock, par value $0.00001 per share | 6,333 | — | — | 6,333 |
| 2026-08-01 | Grant/award | Stock Option (Right to Buy) | 40,800 | — | — | 40,800 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-01 | Grant/award (6,333 shares) |
| 2026-08-01 | Grant/award (40,800 shares) |
Keywords
insider transaction, Form 4, VKTX, Viking Therapeutics, Inc., neutral, Dorothy Elizabeth Kelly-Gemmell
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.